Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Anti-platelet therapy · 1 trial · 1 indication
MAE is defined as any device-related or index procedure-related death within 30 days, myocardial infarction during index hospitalization, target vessel revascularization through 9 months, or amputation of the index limb through 9 months
| Arm | Type | Description |
|---|---|---|
| ORION | EXPERIMENTAL | All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with iliac artery stenting with the Epic™ Nitinol Stent System. |
| Name | Type | Description |
|---|---|---|
| Epic™ Nitinol Stent System | DEVICE | The Epic™ Nitinol Stent System is comprised of two components: the implantable nitinol endoprosthesis and the stent delivery system. |
| Anti-platelet therapy | DRUG | Investigators must prescribe concomitant anti-platelet medication consistent with current clinical practice. Anti-platelet therapy should be administered preprocedure and continued throughout participation in the trial. |
| Anti-coagulation therapy | DRUG | Anti-coagulation therapy must be administered during the procedure consistent with current clinical practice. |
Inclusion Criteria: * Documented chronic, symptomatic iliac artery atherosclerotic disease (Rutherford/Becker category 1, 2, 3 or 4) * Lifestyle-limiting claudication or rest pain * De novo or restenotic lesions in the common and/or external iliac artery * Subjects with bilateral disease may have o...
Anti-platelet therapy is used for the treatment of atherosclerotic lesions in iliac arteries, specifically for Iliac Artery Stenosis. It is being developed by Boston Scientific Corporation (BSX) and is currently in Phase 3 clinical development as an investigational therapy.
Anti-platelet therapy targets platelet aggregation, which plays a role in the formation of atherosclerotic lesions. By inhibiting platelet function, it aims to reduce the risk of thrombotic events in patients with Iliac Artery Stenosis undergoing treatment.
Anti-platelet therapy is developed by Boston Scientific Corporation, a medical device and pharmaceutical company traded on the New York Stock Exchange under the ticker BSX. The company is conducting clinical trials to evaluate the therapy for Iliac Artery Stenosis.
Anti-platelet therapy is in Phase 3 clinical development. It is an investigational therapy and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, with results expected to inform further development decisions.
Anti-platelet therapy has one completed Phase 3 clinical trial, NCT00896337, titled 'EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries.' The trial enrolled 125 participants in the United States and evaluated the therapy for Iliac Artery Stenosis.
Anti-platelet therapy is not the same as the EPIC Nitinol Stent System. The EPIC Nitinol Stent System is a medical device used in the clinical trial NCT00896337, while Anti-platelet therapy refers to the drug treatment being studied in combination with the stent system for Iliac Artery Stenosis.